EMEA-000406-PIP01-08-M04 - paediatric investigation plan

fosaprepitant
PIP Human

Key facts

Invented name
  • Ivemend
  • Ivemend
Active substance
fosaprepitant
Therapeutic area
Oncology
Decision number
P/0010/2014
PIP number
EMEA-000406-PIP01-08-M04
Pharmaceutical form(s)
Powder for solution for infusion
Condition(s) / indication(s)
Prevention of nausea and vomiting
Route(s) of administration
Intravenous use
Contact for public enquiries

Merck Sharp & Dohme (Europe) Inc.
Tel.: +33180464738
E-mail: pip.information@merck.com

Decision type
PM: decision on the application for modification of an agreed PIP
Decision date
Compliance check done
Yes
Compliance procedure number
EMEA-C-000406-PIP01-08-M04
Compliance opinion date
Compliance outcome
Positive

Decision

Share this page